Abstract: Television is the largest advertising category in the United States with over 65 billion spent by advertisers per year. A variety of different targeting algorithms are compared, ranging from the traditional age-gender targeting methods employed based on Nielsen ratings, to new approaches that attempt to target high probability buyers using Set Top Box data. The performance of these different algorithms on a real television campaign is shown, and the advantages and limitations of each method are discussed. In contrast to other theoretical work, all methods presented herein are compatible with targeting the existing 115 million Television households in the United States and are implementable on current television delivery systems.

Abstract: The present disclosure provides methods for treating and improving moderate-to-severe osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of an agent that binds and neutralizes transforming growth factor beta (TGF?).

Abstract: A method of modulating plasma levels of branched chain amino acids and branched chain alpha-keto acids is disclosed, wherein an ammonia scavenger compound or a salt thereof, for example phenylbutyrate or an even numbered congener thereof or a salt thereof, is administered to an individual in need thereof. In various methods, a decrease in plasma levels of branched chain amino acids and branched chain alpha-keto acids is effected to treat individuals suffering from an inborn error in metabolism of amino acids, such as Maple Syrup Urine Disease, for example.

Abstract: The present invention is a computer-implemented method comprising: identifying, by one or more processors, an image of a user; generating, by the one or more processors, an altered image of the user; receiving, by the one or more processors, confirmation that the user has joined a game, and identifying the relationship between the user and the other participants in the game; altering, by the one or more processors, the other participants user interface where the user is shown with the altered image based on a known relationship with the user; and concealing, by the one or more processors, the user's identity from the participants which do not have a relationship with the user.

Abstract: The present invention relates to gene therapy delivery and expression systems comprising at least one helper-dependent adenoviral vector containing a nucleic acid sequence encoding for proteoglycan 4 (PRG4) or a biologically active fragment thereof. The invention further relates to a pharmaceutical composition comprising a therapeutically effective amount of at least one helper-dependent adenoviral vector containing said nucleic acid sequence encoding for proteoglycan 4 (PRG4), or a homolog thereof from any other species, or a biologically active fragment thereof. The invention also relates to the use of the novel gene therapy delivery and expression system according to the invention for use in the prevention and/or treatment of camptodactyly-arthropathy-coxa vara-pericarditis (CACP), or a musculoskeletal disorder such as a joint disorder or Joint disease.

Abstract: The techniques disclosed herein mitigate stochasticity when controlling a mechanical system with artificial intelligence (AI) agents. In some configurations, AI agents are created using data generated by a machine learning model. Stochasticity is segmented temporally into near term and long term, and different strategies are used to address stochasticity in the different timeframes. For example, long term stochasticity may be addressed with changes to the reward function used to train the model. Short term stochasticity may be addressed by applying a margin to the output of an AI agent. Example margins include window averaging, clamps, and statistical process control bounds. In one configuration, AI agents are regression brains that are generated from setpoints inferred by the model from environmental states. The limitations inherent to fitting a regression line to this data may result in some predicted setpoints being outside of an allowed range.

Abstract: The techniques disclosed herein enable utilizing a full range of setpoint values to control a mechanical system. A machine learning model is trained with states collected from the mechanical system. Some of the states may have little to no variation, limiting exploration of possible setpoint values when training the model. To enable a more thorough exploration of possible setpoint values, the states are augmented with a fluctuating delta value that is derived from a fixed setpoint value. For example, a delta outside air temperature may be computed by subtracting outside air temperature, which fluctuates, from a fixed chilled water setpoint. A method of moments computation converts delta values inferred by the model back into absolute values. The absolute values are used to compute a regression equation that is usable by the mechanical system to compute a setpoint action for a given set of input states.

Abstract: Embodiments of the present disclosure concern the treatment and/or prevention of Ehlers-Danlos Syndrome (EDS) or its manifestations using therapeutic compositions, such as oxytocin and/or oxytocin analogues. The therapeutic compositions may decrease symptoms and/or reverse disease progression.

Abstract: The present invention is a computer- implemented method comprising: identifying, by one or more processors, an image of a user; generating, by the one or more processors, an altered image of the user; receiving, by the one or more processors, confirmation that the user has joined a game, and identifying the relationship between the user and the other participants in the game; altering, by the one or more processors, the other participants user interface where the user is shown with the altered image based on a known relationship with the user; and concealing, by the one or more processors, the user’s identity from the participants which do not have a relationship with the user.

Abstract: A method of modulating plasma levels of branched chain amino acids and branched chain alpha-keto acids is disclosed, wherein an ammonia scavenger compound or a salt thereof, for example phenylbutyrate or an even numbered congener thereof or a salt thereof, is administered to an individual in need thereof. In various methods, a decrease in plasma levels of branched chain amino acids and branched chain alpha-keto acids is effected to treat individuals suffering from an inborn error in metabolism of amino acids, such as Maple Syrup Urine Disease, for example.

Abstract: The present invention relates to gene therapy delivery and expression systems comprising at least one helper-dependent adenoviral vector containing a nucleic acid sequence encoding for proteoglycan 4 (PRG4) or a biologically active fragment thereof. The invention further relates to a pharmaceutical composition comprising a therapeutically effective amount of at least one helper-dependent adenoviral vector containing said nucleic acid sequence encoding for proteoglycan 4 (PRG4), or a homolog thereof from any other species, or a biologically active fragment thereof. The invention also relates to the use of the novel gene therapy delivery and expression system according to the invention for use in the prevention and/or treatment of camptodactyly-arthropathy-coxa vara-pericarditis (CACP), or a musculoskeletal disorder such as a joint disorder or joint disease.

Abstract: Systems and methods for digital property authentication and management are disclosed. A document representing a trade secret may be requested to be registered with a trade secret registry. A document obfuscation value corresponding to the document may be generated and may be registered with a blockchain. A record of the registration may be generated for the trade secret registry. The registry may be searchable and/or offer functionality such as valuation, insurance provision, and/or verification, among other benefits and functionalities.

Abstract: The invention resides in a blockchain-implemented method of operating a system having a device, the method comprising: using, processing and/or generating a blockchain transaction (MTx) having: one or more token-related outputs (T-UTXO), each of which represents a respective token (T) issued by a Token Issuer (TI) and specifies a) at least one of the operation, status and data that determines the configuration of the device; b) a quantity of token-related cryptocurrency (TRC) associated with the respective token (T). The operation, status and data that determines the configuration and/or status of the device can be determined from instructions on the output of a respective token's blockchain transaction. Generally, assets or resources can be tracked and/or managed using one or more blockchain transactions in which token-related outputs, representing tokens, function to determine the status of an asset.

Abstract: The invention relates to an adenoviral-based biological delivery and expression system for use in the treatment or prevention of osteoarthritis in human or mammalian joints by long-term inducible gene expression of human or mammalian interleukin-I receptor antagonist (IL-1 Ra) in synovial cells, comprising a helper-dependent adenoviral vector containing a nucleic acid sequence encoding for human or mammalian interleukin-I receptor antagonist (IL-I Ra), left and right inverted terminal repeats (L ITR and R ITR), the adenoviral packaging signal and non-viral, non-coding stuffer nucleic acid sequences, wherein the expression of the human or mammalian interleukin-I receptor antagonist (IL-I Ra) gene within synovial cells is regulated by an inflammation-inducible promoter.

Abstract: The present invention relates to gene therapy delivery and expression systems comprising at least one helper-dependent adenoviral vector containing a nucleic acid sequence encoding for proteoglycan 4 (PRG4) or a biologically active fragment thereof. The invention further relates to a pharmaceutical composition comprising a therapeutically effective amount of at least one helper-dependent adenoviral vector containing said nucleic acid sequence encoding for proteoglycan 4 (PRG4), or a homolog thereof from any other species, or a biologically active fragment thereof. The invention also relates to the use of the novel gene therapy delivery and expression system according to the invention fo ruse in the prevention and/or treatment of camptodactyly-arthropathy-coxa vara-pericarditis (CACP), or a musculoskeletal disorder such as a joint disorder or joint disease.

Abstract: The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGF?).

Abstract: The invention relates to an adenoviral-based biological delivery and expression system for use in the treatment or prevention of osteoathritis in human or mammalian joints by long-term inducible gene expression of human or mammalian interleukin-1 receptor antagonist (II-1 Ra) in synovial cells, comprising a helper-dependent adenoviral vector containing a nucleic acid sequence encoding for human or mammalian interleukin-1 receptor antagonist (II-1 Ra), left and right inverted terminal repeats (L ITR and R ITR), the adenoviral packaging signal and non-viral, non-coding stuffer nucleic acid sequences, wherein the expression of the human or mammalian interleukin-1 receptor antagonist (II-1 Ra) gene within synovial cells is regulated by an inflammation-inducible promoter.

Abstract: The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGF?).

Abstract: The present invention relates to gene therapy delivery and expression systems comprising at least one helper-dependent adenoviral vector containing a nucleic acid sequence encoding for proteoglycan 4 (PRG4) or a biologically active fragment thereof. The invention further relates to a pharmaceutical composition comprising a therapeutically effective amount of at least one helper-dependent adenoviral vector containing said nucleic acid sequence encoding for proteoglycan 4 (PRG4), or a homolog thereof from any other species, or a biologically active fragment thereof. The invention also relates to the use of the novel gene therapy delivery and expression system according to the invention for use in the prevention and/or treatment of camptodactyly-arthropathy-coxa vara-pericarditis (CACP), or a musculoskeletal disorder such as a joint disorder or joint disease.